Where Atara Biotherapeutics Stands With Analysts

Over the past 3 months, 4 analysts have published their opinion on Atara Biotherapeutics (NASDAQ:ATRA) stock. These analysts…

Over the past 3 months, 4 analysts have published their opinion on Atara Biotherapeutics (NASDAQ:ATRA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company’s business to predict how a stock will trade over the upcoming year.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 1 0 1 0 2
Last 30D 0 0 0 0 1
1M Ago 0 0 1 0 0
2M Ago 1 0 0 0 0
3M Ago 0 0 0 0 1

According to 4 analyst offering 12-month price targets in the last 3 months, Atara Biotherapeutics has an average price target of $7.72 with a high of $28.00 and a low of $0.50.

Below is a summary of how these 4 analysts rated Atara Biotherapeutics over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock

price target chart

This current average has decreased by 35.67% from the previous average price target of $12.00.

Stay up to date on Atara Biotherapeutics analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

What Are Analyst Ratings?

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish “analyst ratings” for stocks. Analysts typically rate each stock once per quarter.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

S&P 500, Nasdaq Slip As Tech Underperforms, Oil Reacts to OPEC+: What’s Driving Markets Thursday?

Thursday’s trading session on Wall Street presents a mixed picture, characterized by notable fluctuations in major indices. While tech-heavy benchmarks like the S&P 500 and the Nasdaq 100 are experiencing declines, blue-chip stocks and small caps are treading the path of marginal gains.

AMBA

Read More

UPS’s Strategic Investment Plan Promises Growth, But This Analyst Questions Market Performance Amid Demand Slowdown

BMO Capital Markets analyst Fadi Chamoun reiterates UPS with Market Perform rating with a revised price target of $165, emphasizing the company's strategic focus on premium segments like healthcare logistics and SMBs. However, ambitious revenue targets may face challenges without significant macroeconomic improvements, despite UPS's plans for operational optimization and $3 billion in cost savings by 2026.

UPS